Study Summary
This study is evaluating whether a drug called ketorolac may help reduce the risk of cancer spreading after surgery.
Eligible Conditions
- Kidney Cancer
- Non-small Cell Lung Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
5 Primary · 11 Secondary · Reporting Duration: Baseline, Day 1, Day 3 (if admitted to hospital), Day 7, Day 28
Day 28
Change in Flow Cytometry
Change in Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Levels
Change in Interferon (INF)-gamma Levels
Change in Interleukin-1 alpha (IL-1alpha) Levels
Change in Interleukin-10 (IL-10) Levels
Change in Interleukin-12p70 (IL-12p70) Levels
Change in Interleukin-1beta (IL-1β) Levels
Change in Interleukin-2 (IL-2) Levels
Change in Interleukin-6 (IL-6) Levels
Change in Interleukin-8 (IL-8) Levels
Change in Monocyte Chemotactic and Activating Factor (MCAF) Levels
Change in Single Cell RNA Sequencing
Change in T-Cell Receptor (TCR) Sequencing
Change in Transcriptome Analysis
Change in Tumor Necrosis Factor-alpha (TNF-alpha) Levels
Day 7
Incidence of Blood Transfusion Among Ketorolac Group
Incidence of Clinically Significant Hematoma Development Among Ketorolac Group
Incidence of Postoperative Morbidity Rate Among Ketorolac Group
Incidence of Postoperative Renal Failure Among Ketorolac Group
Hemorrhage
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Control Group
1 of 2
Preoperative Ketorolac
1 of 2
Active Control
Experimental Treatment
76 Total Participants · 2 Treatment Groups
Primary Treatment: Preoperative Ketorolac · No Placebo Group · Phase < 1
Preoperative Ketorolac
Drug
Experimental Group · 1 Intervention: Preoperative Ketorolac · Intervention Types: DrugControl GroupNoIntervention Group · 1 Intervention: Control Group · Intervention Types:
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, day 1, day 3 (if admitted to hospital), day 7, day 28
Who is running the clinical trial?
Emory UniversityLead Sponsor
1,509 Previous Clinical Trials
2,706,093 Total Patients Enrolled
Viraj Master, MD, PhDPrincipal Investigator - Emory University
Emory Saint Joseph's, Emory University Hospital, Emory University Hospital Midtown, Grady Memorial Hospital
University Of Chicago (Medical School)
University Ca Sf School Of Medicine (Residency)
1 Previous Clinical Trials
55 Total Patients Enrolled
Onkar Khullar, MDPrincipal InvestigatorEmory University
Eligibility Criteria
Age 18 - 80 · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments